TWD 70.6
(3.22%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 638.27 Million TWD | 17.72% |
2022 | 542.21 Million TWD | 7.78% |
2021 | 503.07 Million TWD | 22.12% |
2020 | 411.95 Million TWD | -2.27% |
2019 | 421.54 Million TWD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 162.02 Million TWD | 5.73% |
2024 Q2 | 161.6 Million TWD | -0.26% |
2023 Q4 | 153.24 Million TWD | -5.91% |
2023 FY | 638.27 Million TWD | 17.72% |
2023 Q3 | 162.87 Million TWD | -7.65% |
2023 Q2 | 176.36 Million TWD | 20.97% |
2023 Q1 | 145.79 Million TWD | -1.52% |
2022 FY | 542.21 Million TWD | 7.78% |
2022 Q4 | 148.04 Million TWD | 0.0% |
2021 FY | 503.07 Million TWD | 22.12% |
2020 FY | 411.95 Million TWD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
DIVA Laboratories, Ltd. | 250.77 Million TWD | -154.524% |
Genetics Generation Advancement Corp. | 236.83 Million TWD | -169.509% |
Welgene Biotech Co.,Ltd. | 119.71 Million TWD | -433.159% |
Puriblood Medical Co., Ltd. | 6.52 Million TWD | -9685.022% |
TFBS Bioscience Inc. | 77.82 Million TWD | -720.102% |